Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Modular, Open Label, Randomized Phase II/III Trial to Assess Efficacy of Combining SEphB4-HSA (EphrinB2 Inhibitor) with Immunotherapy Regimens in Patients with EphrinB2-High Solid Tumors

Next Previous
Search
Trial Profile

A Modular, Open Label, Randomized Phase II/III Trial to Assess Efficacy of Combining SEphB4-HSA (EphrinB2 Inhibitor) with Immunotherapy Regimens in Patients with EphrinB2-High Solid Tumors

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; SEphB4-HSA (Primary) ; Cisplatin; Enfortumab vedotin; Gemcitabine
  • Indications Carcinoma; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors VasGene Therapeutics

    • Most Recent Events

    • 03 Apr 2025 Status changed from not yet recruiting to recruiting.
    • 19 Sep 2024 Planned initiation date changed from 1 Sep 2024 to 1 Nov 2024.
    • 18 Jul 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top